{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:10:03Z","timestamp":1793988603154,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is the earliest discernible stage of multiple myeloma (MM) and Waldenstr\u00f6m\u2019s macroglobulinemia (WM). Early diagnosis of MG may be compromised by the low-level infiltration, undetectable to low-sensitive methodologies. Here, we investigated the prevalence and immunophenotypic profile of clonal (c) plasma cells (PC) and\/or cB-lymphocytes in bone marrow (BM) and blood of subjects with a serum M-component from the iSTOPMM program, using high-sensitive next-generation flow cytometry (NGF), and its utility in the diagnostic classification of early-stage MG. We studied 164 paired BM and blood samples from 82 subjects, focusing the analysis on: 55 MGUS, 12 smoldering MM (SMM) and 8 smoldering WM (SWM). cPC were detected in 84% of the BM samples and cB-lymphocytes in 45%, coexisting in 39% of cases. In 29% of patients, the phenotypic features of cPC and\/or cB-lymphocytes allowed a more accurate disease classification, including: 19\/55 (35%) MGUS, 1\/12 (8%) SMM and 2\/8 (25%) SWM. Blood samples were informative in 49% of the BM-positive cases. We demonstrated the utility of NGF for a more accurate diagnostic classification of early-stage MG.<\/jats:p>","DOI":"10.1038\/s41408-023-00944-1","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T23:08:58Z","timestamp":1702249738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-4337","authenticated-orcid":false,"given":"Oihane","family":"P\u00e9rez-Escurza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-4387","authenticated-orcid":false,"given":"Juan","family":"Flores-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-1166","authenticated-orcid":false,"given":"J\u00f3n \u00de\u00f3rir","family":"\u00d3skarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-7793","authenticated-orcid":false,"given":"Luzalba","family":"Sanoja-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-5846","authenticated-orcid":false,"given":"Quentin","family":"Lecrevisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00edn Ruth","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u00f0laug Katr\u00edn","family":"H\u00e1konard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-3530","authenticated-orcid":false,"given":"Sigr\u00fan","family":"\u00deorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e6mundur","family":"R\u00f6gnvaldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur Jon","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-7476","authenticated-orcid":false,"given":"Sigur\u00f0ur Yngvi","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7230","authenticated-orcid":false,"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"944_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdeO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"944_CR2","unstructured":"Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 2017."},{"key":"944_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"944_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9:102.","journal-title":"Blood Cancer J"},{"key":"944_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"944_CR6","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"944_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ajh.25117","volume":"93","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93:1091\u2013110.","journal-title":"Am J Hematol"},{"key":"944_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","volume":"29","author":"S Thorsteinsd\u00f3ttir","year":"2023","unstructured":"Thorsteinsd\u00f3ttir S, G\u00edslason GK, Aspelund T, R\u00f6gnvaldsson S, \u00d3skarsson J\u00de, Sigur\u00f0ard\u00f3ttir G\u00c1, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29:467\u201372.","journal-title":"Nat Med"},{"key":"944_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2018;378:241\u20139.","journal-title":"N Engl J Med"},{"key":"944_CR10","first-page":"102","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood. Cancer J. 2020;10:102.","journal-title":"Cancer J"},{"key":"944_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","volume":"106","author":"P Musto","year":"2021","unstructured":"Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, van de Donk N, et al. 2021 European myeloma network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica.2021;106:2799\u2013812.","journal-title":"Haematologica."},{"key":"944_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","volume":"482","author":"F Fend","year":"2023","unstructured":"Fend F, Dogan A, Cook JR. Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch Int J Pathol. 2023;482:163\u201377.","journal-title":"Virchows Arch Int J Pathol"},{"key":"944_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ajh.26082","volume":"96","author":"MA Gertz","year":"2021","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96:258\u201369.","journal-title":"Am J Hematol"},{"key":"944_CR14","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","volume":"107","author":"J Khwaja","year":"2022","unstructured":"Khwaja J, D\u2019Sa S, Minnema MC, Kersten MJ, Wechalekar A, Vos JMI. IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica. 2022;107:2037\u201350.","journal-title":"Haematologica."},{"key":"944_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3816\/CLM.2009.n.002","volume":"9","author":"R Kyle","year":"2009","unstructured":"Kyle R, Benson J, Larson D, Therneau T, Dispenzieri A, Melton LJ, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:17\u20138.","journal-title":"Clin Lymphoma Myeloma"},{"key":"944_CR16","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","volume":"119","author":"RA Kyle","year":"2012","unstructured":"Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S, et al. Progression in smoldering Waldenstr\u00f6m macroglobulinemia: Long-term results. Blood 2012;119:4462\u20136.","journal-title":"Blood"},{"key":"944_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129.","journal-title":"Blood Cancer J"},{"key":"944_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11899-019-00499-8","volume":"14","author":"A Pham","year":"2019","unstructured":"Pham A, Mahindra A. Solitary plasmacytoma: a review of diagnosis and management. Curr Hematol Malig Rep. 2019;14:63\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"944_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pathol.2019.09.009","volume":"52","author":"W Wang","year":"2020","unstructured":"Wang W, Lin P. Lymphoplasmacytic lymphoma and Waldenstr\u00f6m macroglobulinaemia: clinicopathological features and differential diagnosis. Pathology. 2020;52:6\u201314.","journal-title":"Pathology"},{"key":"944_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","volume":"11","author":"S R\u00f6gnvaldsson","year":"2021","unstructured":"R\u00f6gnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, \u00d3skarsson J\u00de, P\u00e9tursd\u00f3ttir \u00cd, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94.","journal-title":"Blood Cancer J"},{"key":"944_CR21","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/blood-2003-01-0045","volume":"102","author":"ML Sanchez","year":"2003","unstructured":"Sanchez ML, Almeida J, Gonzalez D, Gonzalez M, Garcia-Marcos MA, Balanzategui A, et al. Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood. 2003;102:2994\u20133002.","journal-title":"Blood."},{"key":"944_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/CCO.0000000000000331","volume":"28","author":"B Paiva","year":"2016","unstructured":"Paiva B, Merino J, Miguel JFS. Utility of flow cytometry studies in the management of patients with multiple myeloma. Curr Opin Oncol. 2016;28:511\u20137.","journal-title":"Curr Opin Oncol"},{"key":"944_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/ijlh.12757","volume":"40","author":"IV Galtseva","year":"2018","unstructured":"Galtseva IV, Davydova YO, Kapranov NM, Julhakyan HL, Mendeleeva LP. Minimal residual disease in multiple myeloma: Benefits of flow cytometry. Int J Lab Hematol. 2018;40:12\u201320.","journal-title":"Int J Lab Hematol"},{"key":"944_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2019","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3nCord L, En Vidriales MB, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2019;38:784\u201392.","journal-title":"J Clin Oncol"},{"key":"944_CR25","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","volume":"27","author":"KC Anderson","year":"2021","unstructured":"Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, et al. Minimal residual disease in myeloma: application for clinical care and new drug registration. Clin Cancer Res. 2021;27:5195\u2013212.","journal-title":"Clin Cancer Res"},{"key":"944_CR26","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next-generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia."},{"key":"944_CR27","doi-asserted-by":"publisher","first-page":"112662","DOI":"10.1016\/j.jim.2019.112662","volume":"475","author":"J Flores-Montero","year":"2019","unstructured":"Flores-Montero J, Grigore G, Flux\u00e1 R, Hern\u00e1ndez J, Fernandez P, Almeida J, et al. EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. J Immunol Methods. 2019;475:112662.","journal-title":"J Immunol Methods"},{"key":"944_CR28","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJM van Dongen","year":"2012","unstructured":"van Dongen JJM, Lhermitte L, B\u00f6ttcher S, Almeida J, van Der Velden VHJ, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908\u201375.","journal-title":"Leukemia."},{"key":"944_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41375-022-01762-3","volume":"37","author":"I Dogliotti","year":"2023","unstructured":"Dogliotti I, Jim\u00e9nez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, et al. Diagnostics in Waldenstr\u00f6m\u2019s macroglobulinemia: a consensus statement of the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia. Leukemia. 2023;37:388\u201395.","journal-title":"Leukemia."},{"key":"944_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/sonc.2003.50074","volume":"30","author":"JF San Miguel","year":"2003","unstructured":"San Miguel JF, Vidriales MB, Ocio E, Mateo G, S\u00e1nchez-Guijo F, S\u00e1nchez ML, et al. Immunophenotypic analysis of Waldenstrom\u2019s macroglobulinemia. Semin Oncol. 2003;30:187\u201395.","journal-title":"Semin Oncol"},{"key":"944_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/leu.2013.124","volume":"28","author":"B Paiva","year":"2014","unstructured":"Paiva B, Montes MC, Garc\u00eda-Sanz R, Ocio EM, Alonso J, De Las Heras N, et al. Multiparameter flow cytometry for the identification of the Waldenstr\u00f6m\u2019s clone in IgM-MGUS and Waldenstr\u00f6m\u2019s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia. 2014;28:166\u201373.","journal-title":"Leukemia."},{"key":"944_CR32","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1182\/blood-2022-164758","volume":"140","author":"R Palmason","year":"2022","unstructured":"Palmason R, Berlanga O, Sigurdsson JK, R\u00f6gnvaldsson S, Thorsteinsdottir S, Ekberg S, et al. Transient M-proteins: epidemiology, causes, and the impact of mass spectrometry: the Istopmm study. Blood. 2022;140:2338\u201340.","journal-title":"Blood."},{"key":"944_CR33","doi-asserted-by":"publisher","first-page":"112287","DOI":"10.1016\/j.jim.2017.03.011","volume":"475","author":"VHJ van der Velden","year":"2019","unstructured":"van der Velden VHJ, Flores-Montero J, Perez-Andres M, Martin-Ayuso M, Crespo O, Blanco E, et al. Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples. J Immunol Methods. 2019;475:112287.","journal-title":"J Immunol Methods"},{"key":"944_CR34","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van Der Velden VHJ, Martin-Ayuso M, B\u00f6ttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986\u20132010.","journal-title":"Leukemia."},{"key":"944_CR35","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, Vidriales MB, Mateo G, Garc\u00eda-Sanz R, Mateos MV, De Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586\u201392.","journal-title":"Blood."},{"key":"944_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","volume":"126","author":"P Strati","year":"2015","unstructured":"Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126:454\u201362.","journal-title":"Blood."},{"key":"944_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/BLCTT.S259860","volume":"12","author":"S Cingam","year":"2022","unstructured":"Cingam S, Sidana S. Differential diagnosis of Waldenstr\u00f6m\u2019s macroglobulinemia and early management: perspectives from clinical practice. Blood Lymphat Cancer Targets Ther. 2022;12:107\u201317.","journal-title":"Blood Lymphat Cancer Targets Ther"},{"key":"944_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","volume":"11","author":"D Murray","year":"2021","unstructured":"Murray D, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021;11:24.","journal-title":"Blood Cancer J"},{"key":"944_CR39","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","volume":"62","author":"JR Mills","year":"2016","unstructured":"Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62:1334\u201344.","journal-title":"Clin Chem"},{"key":"944_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1182\/blood.2022017439","volume":"141","author":"G Oliva-Ariza","year":"2023","unstructured":"Oliva-Ariza G, Fuentes-Herrero B, Carbonell C, Lecrevisse Q, P\u00e9rez-Pons A, Torres-Valle A, et al. High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients. Blood. 2023;141:309\u201314.","journal-title":"Blood."},{"key":"944_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812\u20137.","journal-title":"Blood."},{"key":"944_CR42","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139.","journal-title":"N Engl J Med"},{"key":"944_CR43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","volume":"123","author":"I Turesson","year":"2014","unstructured":"Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338\u201345.","journal-title":"Blood."},{"key":"944_CR44","unstructured":"Garc\u00eda Mateo A. Gammapat\u00eda Monoclonal de Significado Incierto en la provincia de Segovia: Estudio poblacional y factores pron\u00f3sticos (c\u00e9lulas plasm\u00e1ticas en sangre perif\u00e9rica por inmunofenotipo y ensayo de cadena pesada-ligera de las inmunoglobulinas). 2019."},{"key":"944_CR45","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/ajh.24753","volume":"92","author":"JJ Castillo","year":"2017","unstructured":"Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, et al. IgM myeloma: a multicenter retrospective study of 134 patients. Am J Hematol. 2017;92:746\u201351.","journal-title":"Am J Hematol"},{"key":"944_CR46","doi-asserted-by":"crossref","unstructured":"Lagan\u00e0 A, Parekh S.Distinct) origins of IgM myeloma.Blood. 2021;138:1914\u20135..","DOI":"10.1182\/blood.2021013860"},{"key":"944_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/ajcp\/aqab095","volume":"157","author":"H Lu","year":"2022","unstructured":"Lu H, Durkin L, Zhao X, Nakashima MO. IgM plasma cell myeloma. Am J Clin Pathol. 2022;157:47\u201353.","journal-title":"Am J Clin Pathol"},{"key":"944_CR48","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1515\/cclm-2015-0862","volume":"54","author":"DF Keren","year":"2016","unstructured":"Keren DF, Schroeder L. Challenges of measuring monoclonal proteins in serum. Clin Chem Lab Med. 2016;54:947\u201361.","journal-title":"Clin Chem Lab Med"},{"key":"944_CR49","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1373\/clinchem.2009.124461","volume":"55","author":"DL Murray","year":"2009","unstructured":"Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem. 2009;55:1523\u20139.","journal-title":"Clin Chem"},{"key":"944_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/labmed\/lmz055","volume":"51","author":"A Clavijo","year":"2019","unstructured":"Clavijo A, Ryan N, Xu H, Singh G. Measurement of monoclonal immunoglobulin protein concentration in serum protein electrophoresis: comparison of automated vs manual\/human readings. Lab Med. 2019;51:252\u20138.","journal-title":"Lab Med"},{"key":"944_CR51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","volume":"8","author":"L Sanoja-Flores","year":"2018","unstructured":"Sanoja-Flores L, Flores-Montero J, Garc\u00e9s JJ, Paiva B, Puig N, Garc\u00eda-Mateo A, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8:117.","journal-title":"Blood Cancer J"},{"key":"944_CR52","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"JJ Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s JJ, Cedena MT, Puig N, Burgos L, Perez JJ, Cordon L, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol. 2022;40:3151\u201361.","journal-title":"J Clin Oncol"},{"key":"944_CR53","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1038\/s41375-020-0883-0","volume":"34","author":"JJ Garc\u00e9s","year":"2020","unstructured":"Garc\u00e9s JJ, Bretones G, Burgos L, Valdes-Mas R, Puig N, Cedena MT, et al. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia. 2020;34:3007\u201318.","journal-title":"Leukemia."},{"key":"944_CR54","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","volume":"28","author":"R Termini","year":"2022","unstructured":"Termini R, \u017dihala D, Terpos E, Perez-Monta\u00f1a A, Jel\u00ednek T, Raab M, et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res. 2022;28:4771\u201381.","journal-title":"Clin Cancer Res"},{"key":"944_CR55","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106:2276\u20139.","journal-title":"Blood."},{"key":"944_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14061430","volume":"14","author":"JJ Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s JJ, San-Miguel J, Paiva B. Biological characterization and clinical relevance of circulating tumor cells: opening the pandora\u2019s box of multiple myeloma. Cancers. 2022;14:1\u201311.","journal-title":"Cancers."},{"key":"944_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061499","volume":"12","author":"L Sanoja-Flores","year":"2020","unstructured":"Sanoja-Flores L, Flores-Montero J, P\u00e9rez-Andr\u00e9s M, Puig N, Orfao A. Detection of circulating tumor plasma cells in monoclonal gammopathies: methods, pathogenic role, and clinical implications. Cancers. 2020;12:1\u201326.","journal-title":"Cancers."},{"key":"944_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-3532-1_1","volume":"1254","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu J, Burrows PD, Wang JY. B cell development and maturation. Adv Exp Med Biol. 2020;1254:1\u201322.","journal-title":"Adv Exp Med Biol"},{"key":"944_CR59","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2010.320","volume":"25","author":"B Paiva","year":"2011","unstructured":"Paiva B, P\u00e9rez-Andr\u00e9s M, V\u00eddriales MB, Almeida J, De Las Heras N, Mateos MV, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 2011;25:697\u2013706.","journal-title":"Leukemia."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00944-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:03:06Z","timestamp":1702288986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00944-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00944-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JF-M and AO are inventors of the EuroFlow-owned patents PCT\/NL2010\/050332 (Methods, reagents, and kits for flow cytometric immunophenotyping of normal, reactive and malignant leukocytes) and PCT\/NL20 13\/050420 (Methods, reagents and kits for detecting minimal residual disease), licensed to BD Biosciences (San Jos\u00e9, CA, USA) which pay royalties to the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow Consortium. SYK has received research funding from Amgen and Celgene. SH is currently employed by The Binding Site. OP-E, J\u00deO, LS-F, JP, QL, SM, ERR, GKH, and BD declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}